 |
80 Diseases |  |
201 Trials |
|
201 Trials |  |
5390 News |  |
| «12...4567891011121314...6970» |
- | Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Journal, Metastases: Scrotal Paget's Disease Associated With Human Epidermal Growth Factor Receptor 2-Overexpressing Metastatic Apocrine Carcinoma With Complete Response to Paclitaxel, Trastuzumab, and Pertuzumab. (Pubmed Central) - Aug 22, 2023
No abstract available
- Herceptin (trastuzumab) / Roche
Does Dual Anti-HER2 Therapy Increase Early Cardiac Toxicity in Comparison with Trastuzumab Alone in Breast Cancer Patients Receiving Adjuvant Radiotherapy? A Multicenter Retrospective Study (Hall B2; In Person Only; Screen: 2) - Aug 22, 2023 - Abstract #ASTRO2023ASTRO_841;
Compared with trastuzumab-only, dual anti-HER2 therapy does not increase early cardiac toxicity in combination with adjuvant RT in BC patients. Cardiac radiation exposure remains the primary risk factor associated with early cardiac toxicity.
- Safety and Efficacy of Stereotactic Radiosurgery with Concurrent Targeted Systemic Therapy for Brain Metastases (Hall B2; In Person Only; Screen: 11) - Aug 22, 2023 - Abstract #ASTRO2023ASTRO_663;
Although heterogeneous, patients treated with SRS/SRT and ongoing CNS-active targeted systemic therapies have on average >6 month intracranial PFS and little evidence of significant toxicity. We observed <6% G2+ radiation necrosis for this cohort, and no particular class of agent was associated with a significantly higher rate of G2+ radiation necrosis.
- | Perjeta (pertuzumab) / Roche, Trazimera (trastuzumab-qyyp) / Pfizer
Biomarker, Trial completion date: NCI-2016-00570: Cu64-DOTA-trastuzumab PET and Markers Predicting Response to Neoadjuvant Trastuzumab + Pertuzum in HER2+ Breast Cancer (clinicaltrials.gov) - Aug 22, 2023
P2, N=18, Active, not recruiting, Sponsor: City of Hope Medical Center
We observed <6% G2+ radiation necrosis for this cohort, and no particular class of agent was associated with a significantly higher rate of G2+ radiation necrosis. Trial completion date: Jun 2023 --> Dec 2023
- ||| pertuzumab biosimilar / Mabscale
Enrollment open: Study, Evaluating Pharmacokinetics, Immunogenicity and Safety Profiles of Pertuzumab Compared to Perjeta (clinicaltrials.gov) - Aug 22, 2023
P1, N=114, Recruiting, Sponsor: Mabscale, LLC
Trial completion date: Jun 2023 --> Dec 2023 Not yet recruiting --> Recruiting
- | Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Journal, Real-world evidence, Real-world, Metastases: Real-World Impact of Adjuvant Anti-HER2 Treatment on Characteristics and Outcomes of Women With HER2-Positive Metastatic Breast Cancer in the ESME Program. (Pubmed Central) - Aug 17, 2023
Not yet recruiting --> Recruiting Among patients with relapsed HER2+ MBC, the receipt of adjuvant trastuzumab did not independently predict for worse outcomes when adjusted to other prognostic factors.
- | Irene (pyrotinib) / Jiangsu Hengrui Pharma
Journal, Real-world evidence, Real-world, Metastases: Long-term Outcome Analysis of Pyrotinib in Patients With HER2-Positive Metastatic Breast Cancer and Brain Metastasis: A Real-World Study. (Pubmed Central) - Aug 17, 2023
Among patients with relapsed HER2+ MBC, the receipt of adjuvant trastuzumab did not independently predict for worse outcomes when adjusted to other prognostic factors. Long-term outcomes of pyrotinib-based therapy are promising for patients with HER2-positive metastatic breast cancer in real world and in patients with BM, regardless of the treatment lines and prior anti-HER2 therapies.
- | Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Journal: Binding Affinity of Trastuzumab and Pertuzumab Monoclonal Antibodies to Extracellular HER2 Domain. (Pubmed Central) - Aug 16, 2023
Furthermore, experiments revealed that the pertuzumab IgG antibody binds preferentially to two HER2 proteins, one per Fab fragment, while trastuzumab mainly forms a monovalent complex. This finding was interpreted based on a geometrical model that identified steric crowding in the trastuzumab-HER2 complex as compared with the pertuzumab-HER2 complex.
- |||||||||| TQB2440 (pertuzumab biosimilar) / Sino Biopharm
New P3 trial, Metastases: Clinical Study to Evaluate the Efficacy and Safety of TQB2440 Injection/Perjeta (clinicaltrials.gov) - Aug 14, 2023
P3, N=412, Active, not recruiting, Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- | Perjeta (pertuzumab) / Roche
Journal, Combination therapy: A cost-consequence analysis of adding pertuzumab to the neoadjuvant combination therapy in HER2-positive high-risk early breast cancer in Italy. (Pubmed Central) - Aug 13, 2023
This finding was interpreted based on a geometrical model that identified steric crowding in the trastuzumab-HER2 complex as compared with the pertuzumab-HER2 complex. Our findings suggested that TPC combination could be a cost-saving option in patients with HER2+BC at high-risk of recurrence.
- || Enhertu (fam-trastuzumab deruxtecan-nxki) / Daiichi Sankyo, AstraZeneca, Perjeta (pertuzumab) / Roche
Review, Journal: PET/CT and SPECT/CT Imaging of HER2-Positive Breast Cancer. (Pubmed Central) - Aug 12, 2023
Additionally, PET and SPECT could help evaluate effectiveness of HER2-targeted therapies, such as trastuzumab or pertuzumab for HER2-positive cancers, and specially modified antibody drug conjugates (ADC), such as trastuzumab-deruxtecan, for HER2-low variants. This review will explore the current and future role of HER2 imaging in personalizing the care of patients diagnosed with breast cancer.
- || Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Clinical, Journal, Metastases: Pertuzumab Plus Trastuzumab With or Without Chemotherapy Followed by Emtansine in ERBB2-Positive Metastatic Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial. (Pubmed Central) - Aug 10, 2023
P2
The 50-gene prediction analysis of microarray signature could not help to identify the most appropriate patient population for this approach. ClinicalTrials.gov Identifier: NCT01835236.
- | utidelone IV (UTD1) / Beijing Biostar Technologies
New P2 trial, Metastases: Study of Utidelone Based Neoadjuvant Treatment on Early High-risk or Locally Advanced Breast Cancer (clinicaltrials.gov) - Aug 9, 2023
P2, N=181, Not yet recruiting, Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- | Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Journal: Determination of HER2 binding domain in antigen-antibody complexes based on chemical crosslinking mass spectrometry. (Pubmed Central) - Aug 7, 2023
We suggest that all established CDI and DSSO crosslinks should be comprehensively considered for correct binding domain analysis because predictions solely based on DSSO might be ambiguous. We have determined the binding interface in the HER2-H-mab using CDI and DSSO, which is the first successful application of XL/MS in real-world early-stage biopharmaceutical development.
- | Cosela (trilaciclib) / G1 Therap
New P2 trial: SMA-BC-002: Trilaciclib in Patients With Early-Stage HR-negative Breast Cancer Receiving Adjuvant Chemotherapy (clinicaltrials.gov) - Aug 7, 2023
P2, N=116, Not yet recruiting, Sponsor: wang shusen
- | Irene (pyrotinib) / Jiangsu Hengrui Pharma
Observational data, Journal, HEOR, Real-world evidence, Real-world, Metastases: Real-world treatment patterns and outcomes of pyrotinib-based therapy in patients with HER2-positive advanced breast cancer (PRETTY): A nationwide, prospective, observational study. (Pubmed Central) - Aug 6, 2023
In real world, pyrotinib-based therapy shows promising effectiveness in the first-, as well as second- and later-line treatment, with acceptable tolerability. Further investigations regarding front-line use or novel combinations of pyrotinib might facilitate to maximize its anti-tumor potential.
- | Perjeta (pertuzumab) / Roche
Enrollment change: Testing a New Imaging Agent to Identify Cancer (clinicaltrials.gov) - Aug 4, 2023
P1, N=60, Recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Further investigations regarding front-line use or novel combinations of pyrotinib might facilitate to maximize its anti-tumor potential. N=20 --> 60
- Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
DEVELOPMENT OF PAH ON LONG-TERM PERTUZUMAB/TRASTUZUMAB THERAPY FOR BREAST CANCER (Convention Center Exhibit Hall - Rapid Area 4C) - Aug 4, 2023 - Abstract #CHEST2023CHEST_2487;
- | Perjeta (pertuzumab) / Roche
Journal: Relevance of Coding Variation in FLG And DOCK8 in Finnish Pediatric Patients with Early-Onset Moderate-To-Severe Atopic Dermatitis. (Pubmed Central) - Aug 3, 2023
Loss-of-function variants, previously reported pathogenic variants, or statistically significant enrichment of nonsynonymous coding region variants were not found in the 13 candidate genes studied by amplicon sequencing. However, higher IgE and eosinophil counts were found in carriers of potentially pathogenic DOCK8 missense variants, suggesting that the role of DOCK8 variation in AD should be further investigated in larger cohorts.
- | Journal: Monoclonal antibodies and antibody-drug conjugates as emerging therapeutics for breast cancer treatment. (Pubmed Central) - Jul 31, 2023
The creation of novel technologies utilizing modified antibodies, such as fragments, conjugates, and multispecific antibodies, must be a central focus of future studies. This review will help scientists working on developing mAbs to treat cancers more effectively.
- | Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Journal, Metastases: Treatment Strategies for HER2-Positive Metastatic Colorectal Cancer (Pubmed Central) - Jul 31, 2023
The TRIUMPH trial was conducted in Japan for patients with HER2-positive colorectal cancer, and its results led to the approval of the combination therapy of pertuzumab and trastuzumab for the treatment of HER2-positive unresectable advanced or recurrent colorectal cancer that has progressed during chemotherapy in March 2022 in Japan. In the field of colorectal cancer, the development of new HER2-targeted drugs such as antibody-drug conjugates and bispecific antibodies is ongoing, and future developments are expected to be of interest.
- || ZN-A-1041 / Roche
Trial completion date, Trial primary completion date, Metastases: A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Patients With HER2-Positive Advanced Solid Tumors (clinicaltrials.gov) - Jul 31, 2023
P1, N=210, Recruiting, Sponsor: Suzhou Zanrong Pharma Limited
In the field of colorectal cancer, the development of new HER2-targeted drugs such as antibody-drug conjugates and bispecific antibodies is ongoing, and future developments are expected to be of interest. Trial completion date: Nov 2023 --> Oct 2024 | Trial primary completion date: Mar 2023 --> Oct 2023
- Kadcyla (ado-trastuzumab emtansine) / Roche, Perjeta (pertuzumab) / Roche
Nodular Regenerative Hyperplasia in a Patient Treated for Triple Positive Breast Cancer (Exhibit Hall) - Jul 29, 2023 - Abstract #ACG2023ACG_4435;
She was started on TCHP (docetaxel, carboplatin, trastuzumab, pertuzumab) every 3 weeks for 6 cycles followed by mastectomy and then Kadcyla based on the KATHERINE study...(H&E; 400x) (F) Dilated shunt vessel extending into the hepatic lobule. (H&E; 400x)
- Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Gastric Linitis Plastica - An Unusual Presentation of Metastatic Breast Cancer (Exhibit Hall) - Jul 29, 2023 - Abstract #ACG2023ACG_3306;
She had been tried on famotidine and ondansetron without relief for a presumed diagnosis of GERD...She was started on docetaxel, trastuzumab and pertuzumab with a good response...(b) Diffuse gastric wall thickening with hyperenhancement was present throughout the entire stomach. (c) Deformity and poor distensibility in the gastric body, concerning for linitis plastica.
- Development of Celiac Disease After Immunotherapy for Psoriasis, Breast Cancer, and Renal Cell Carcinoma: A Case Series (Exhibit Hall) - Jul 29, 2023 - Abstract #ACG2023ACG_1756;
Case Description/ A 21 year old female with psoriasis on ixekizumab (IL-17A antagonist) and recent dose of risankizumab (IL-23A antibody) presented with abdominal pain, diarrhea, and bloating...Colonoscopy showed lymphocytic colitis, and she started budesonide and gluten free diet with some improvement...A 49 year old female with invasive ductal carcinoma was treated with leuprolide, exemestane, trastuzumab and pertuzumab (anti-HER2 antibodies) and developed severe watery diarrhea requiring hospitalization for electrolyte abnormalities and total parenteral nutrition...An 82 year old male with metastatic renal cell carcinoma was treated with axitinib, complicated by diarrhea requiring dose reduction, and pembrolizumab, discontinued due to colitis requiring prednisone, then cabozantinib, complicated by diarrhea which persisted after dose reduction...Figure: Figure: Duodenal Biopsy of Case 3, Celiac Disease in an 82 year old male with metastatic renal cell carcinoma treated with axitinib, pembrolizumab, and cabozantinib. (A) Routine H&E staining of a duodenal biopsy showed subtotal to total villous atrophy, (B) Duodenal biopsy with thickened sub-epithelial collagen layer highlighted on trichrome stain, (C) Duodenal biopsy with intraepithelial lymphocytosis confirmed by CD3 immunohistochemistry Table: Immunotherapies and Presentations of Celiac Disease
- Kadcyla (ado-trastuzumab emtansine) / Roche, Perjeta (pertuzumab) / Roche
The Importance of Monitoring Liver Function in Chemotherapy Patients: A Case Report on Sinusoidal Obstruction Syndrome (Exhibit Hall) - Jul 29, 2023 - Abstract #ACG2023ACG_1508;
An alternative approach to mitigate hepatotoxicity is switching to a safer alternative, as demonstrated in this case where replacing T-DM1 with trastuzumab led to significant improvement in liver function. Figure: Graphic 1: Course of liver enzymes over time
- Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Metastatic Breast Cancer Masquerading as Colonic Mass (Exhibit Hall) - Jul 29, 2023 - Abstract #ACG2023ACG_689;
The analysis of cases as the one above can lay the groundwork in forming cohort of patients to study the polarity of metastatic patterns. Figure: (a)diffuse wall thickening of descending colon (b) coronal view, notable for gastric abutment of transverse colon (c) tissue sample demonstrating linear single-file cells, ER +, PR-, resembling histologically primary breast lesion
- | Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Trial completion date: Paclitaxel + Trastuzumab + Pertuzumab as Pre-Op for Inflammatory BrCa (clinicaltrials.gov) - Jul 28, 2023
P2, N=23, Active, not recruiting, Sponsor: Dana-Farber Cancer Institute
Figure: (a)diffuse wall thickening of descending colon (b) coronal view, notable for gastric abutment of transverse colon (c) tissue sample demonstrating linear single-file cells, ER +, PR-, resembling histologically primary breast lesion Trial completion date: Mar 2023 --> Mar 2024
- ||| Ibrance (palbociclib) / Pfizer
Trial completion, Trial primary completion date, Combination therapy: To Reduce the Use of Chemotherapy in Postmenopausal Patients With ER-positive and HER2-positive Breast Cancer (TOUCH) (clinicaltrials.gov) - Jul 27, 2023
P2, N=144, Completed, Sponsor: ETOP IBCSG Partners Foundation
Trial completion date: Mar 2023 --> Mar 2024 Active, not recruiting --> Completed | Trial primary completion date: Apr 2023 --> Jan 2023
- The IMPRESS-Norway trial: Improving public cancer care by implementing precision cancer medicine in Norway - Safety analysis of the first 126 patients included in the trial () - Jul 27, 2023 - Abstract #ESMO2023ESMO_2279;
P2
All drugs are used outside of their current indications. These first results show safety profiles consistent with toxicities reported in earlier trials.
- Irene (pyrotinib) / Jiangsu Hengrui Pharma, Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Clinical outcomes of pyrotinib-based therapy after prior trastuzumab and pertuzumab in HER2-positive metastatic breast cancer () - Jul 27, 2023 - Abstract #ESMO2023ESMO_2060;
The most common adverse events was diarrhea in the study. Conclusions This study first retrospectively analyze the value of pyrotinib in the era of dual anti-HER2 therapy, preliminarily showing good efficacy and safety of pyrotinib in patients after prior trastuzumab and pertuzumab.
- ADC2122 / ZovaBio, Adcoris, Perjeta (pertuzumab) / Roche
Phase I study of ZV0203, a first in class pertuzumab ADC, in patients with HER2+ advanced solid tumors () - Jul 27, 2023 - Abstract #ESMO2023ESMO_2045;
P1
Conclusions ZV0203 has a manageable safety profile with preliminary antitumor activity in heavily pretreated pts with HER2+ cancer. Further evaluation at higher doses is underway.
- Irene (pyrotinib) / Jiangsu Hengrui Pharma, Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Pyrotinib plus trastuzumab versus pertuzumab plus trastuzumab in patients with HER2-positive metastatic breast cancer: A multicenter, retrospective study () - Jul 27, 2023 - Abstract #ESMO2023ESMO_2034;
P=N/A
Conclusions In real-world setting, although HP showed unshakable position when combined with taxane in first-line treatment, PyroH presented comparable effectiveness in post second-line treatment and patients with brain metastasis and even better efficacy in patients without combination of taxane. Toxicities in both groups were tolerable.
- anbenitamab (KN026) / Alphamab
Two-year follow-up data on the efficacy and safety of KN026, a HER2-targeted bispecific antibody combined with docetaxel as first-line treatment for HER2-positive recurrent/metastatic breast cancer () - Jul 27, 2023 - Abstract #ESMO2023ESMO_2026;
P2
After 2 years follow-up, mPFS was 25.4m and the 30-m OS rate was 83.7%, which is very promising. Robustness of efficacy and safety results will be further confirmed in an ongoing randomized phase 3 clinical trial with PTH as control.
- Kadcyla (ado-trastuzumab emtansine) / Roche, Perjeta (pertuzumab) / Roche
Patients treated with pertuzumab followed by T-DM1 for breast cancer in France from 2014 to 2021: A survival analysis of 10,408 patients from the French National Hospital discharge summary database (PMSI) () - Jul 27, 2023 - Abstract #ESMO2023ESMO_2018;
Risk factors were : a code for liver or cerebromeningeal metastases, undernutrition, and age. Conclusions To our knowledge, this is the largest real-life cohort of patients with breast cancer treated with Pertuzumab followed by T-DM1, and our results are consistent with available data, both from the lead CLEOPATRA and EMILIA studies and other retrospective studies.
- Ogivri (trastuzumab-dkst) / Biocon, Herceptin (trastuzumab) / Roche
Adherence to standardized and structured electronic symptom reporting (ePRO) via mobile app in HER2-positive breast cancer treated with HER2 biosimilar trastuzumab () - Jul 27, 2023 - Abstract #ESMO2023ESMO_1991;
P=N/A
Conclusions To our knowledge, this is the largest real-life cohort of patients with breast cancer treated with Pertuzumab followed by T-DM1, and our results are consistent with available data, both from the lead CLEOPATRA and EMILIA studies and other retrospective studies. Methods In this 6 week observational study, patients were treated with trastuzumab (Ogivri
- Cipterbin (inetetamab) / 3SBio, Perjeta (pertuzumab) / Roche
Neoadjuvant inetetamab combined with pertuzumab, paclitaxel and carboplatin for locally advanced HER2-positive breast cancer: Primary analysis of a phase II study () - Jul 27, 2023 - Abstract #ESMO2023ESMO_1980;
P2
No significant reduction in the left ventricular ejection fraction was observed in any patient. Conclusions Neoadjuvant therapy with TCbIP has shown promising efficacy and manageable toxicity in patients with HER2-positive LA breast cancer.
- Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Evaluation of a composite PET/CT and HER2 tissue-based biomarker to predict response to neoadjuvant HER2-directed therapy in early breast cancer (TBCRC026) () - Jul 27, 2023 - Abstract #ESMO2023ESMO_1953;
P2
Conclusions The composite HER2/PET biomarker had high prediction power for pCR, however was not superior to the prediction power of PET/CT alone. These data suggest clinical trials informed by early FDG PET/CT biomarkers warrant further evaluation to personalize breast cancer care.
- Perjeta (pertuzumab) / Roche
Multiplexed immunofluorescence (mIF) to select patients with HER2+ breast cancer (BC) having an excellent outcome without chemotherapy (chemo): A substudy of the PERNETTA trial (SAKK22/10-UCBG-BOOG) () - Jul 27, 2023 - Abstract #ESMO2023ESMO_1926;
Background PERNETTA trial randomized 210 HER2+ BC patients (pts) to 1st-line trasutuzmab-pertuzumab (T-P) alone or combined with chemo...mIF allowing to assess simultaneously several biomarkers presence, intensity and location seems to permit selecting pts with HER2+ advanced stage BC having an excellent outcome in terms of PFS and OS without chemo in 1st line. If validated these biomarkers may contribute to treatment de-escalation and quality of life improvement.
- Nerlynx (neratinib) / Puma, Knight Therap, Pierre Fabre
Patient profiles treated with extended adjuvant neratinib in the early access registry study: NEAR study () - Jul 27, 2023 - Abstract #ESMO2023ESMO_1903;
P
In the neoadjuvant setting, most patients received trastuzumab + pertuzumab (58.7%) and trastuzumab (31.7%), whereas in the adjuvant setting, anti-HER2 treatment mainly consisted of trastuzumab (79.6%). Conclusions Patients treated in this EAP reflected the profile of patients who were expected to receive extended adjuvant neratinib during the observational period, which included the use of more recent (neo)adjuvant treatments.
- Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Pathological complete response after neoadjuvant chemotherapy plus pertuzumab and trastuzumab for HER2+ early breast cancer: Real-world data from NeoPowER study () - Jul 27, 2023 - Abstract #ESMO2023ESMO_1887;
Only ER expression (OR: 0.97 p=0.004) confirmed its statistical relation to pCR at multivariate analysis. Conclusions NeoPowER study confirms the efficacy of neoadjuvant chemotherapy combined with dual HER2 directed therapy: a higher pCR rate is achievable in case of HR negative and ki67?30% in pts receiving neoadjuvant P+H+CT, when compared to H+CT.
- anbenitamab (KN026) / Alphamab
KN026 in combination with docetaxel as neoadjuvant treatment for HER2+ early or locally advanced breast cancer (BC): A single-arm, multicenter, phase II study () - Jul 27, 2023 - Abstract #ESMO2023ESMO_1868;
P2
Conclusions KN026 plus docetaxel as neoadjuvant treatment has shown promising clinical benefit and acceptable safety for pts with HER2+ early or LABC. Further validation in a large-scale randomized controlled trial is warranted.
- QL1209 (pertuzumab biosimilar) / Qilu Pharma, Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Neoadjuvant QL1209 (a pertuzumab biosimilar) compared with pertuzumab plus trastuzumab and docetaxel in early or locally advanced, HER2-positive, ER(-)/PR(-) breast cancer: A multicenter, randomized, double-blind, equivalence, phase III study () - Jul 27, 2023 - Abstract #ESMO2023ESMO_1866;
P3
Incidences of ADA and Nab were similar between 2 groups (2.3% vs 3.1%; 0.8% vs 0.8%). Table: 245P Conclusions QL1209 demonstrated equivalence to P in efficacy and showed comparable safety profile and immunogenicity in patients with early or locally advanced HER2-positive breast cancer.
- Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Integration of metabolomics and transcriptomics to reveal potential biomarkers associated with treatment response of neoadjuvant therapy in HER2+ breast cancer () - Jul 27, 2023 - Abstract #ESMO2023ESMO_1798;
39 altered pathways aberrantly expressed at both metabolic and transcriptional levels. Conclusions Metabolomics integrated with transcriptomics analysis could assist for gaining more insights into biochemical pathophysiology and facilitate the development of novel therapeutic targets for insensitive patients.
- Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Correlation between trophoblast cell-surface antigen-2 (Trop-2) expression and pathological complete response (pCR) in HER2-positive early breast cancer (EBC): A sub analysis of PHERGain trial () - Jul 27, 2023 - Abstract #ESMO2023ESMO_1794;
Conclusions Metabolomics integrated with transcriptomics analysis could assist for gaining more insights into biochemical pathophysiology and facilitate the development of novel therapeutic targets for insensitive patients. Methods Trop-2 expression, as determined by immunohistochemistry (IHC) and its relationship with clinicopathologic features and pCR, was retrospectively analyzed in patients (pts) with HER2-positive EBC treated with upfront neoadjuvant docetaxel, carboplatin, trastuzumab, and pertuzumab in the PHERGain study (P
- Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Validation of a genomic assay in early-stage HER2+ breast cancer (BC) treated with trastuzumab and pertuzumab (HP): A correlative analysis from PHERGain phase II trial () - Jul 27, 2023 - Abstract #ESMO2023ESMO_1779;
P2
Methods Trop-2 expression, as determined by immunohistochemistry (IHC) and its relationship with clinicopathologic features and pCR, was retrospectively analyzed in patients (pts) with HER2-positive EBC treated with upfront neoadjuvant docetaxel, carboplatin, trastuzumab, and pertuzumab in the PHERGain study (P Patients (pts) with newly diagnosed stage I-IIIA HER2+ BC and PET evaluable lesions were randomized (1:4) to receive either docetaxel (T), carboplatin (C), and HP (group A) or HP
- Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Assessing the effect of single dose trastuzumab and pertuzumab (HP) on biological changes and pathological complete response (pCR) in ERBB2+ Breast Cancer: Results from the neoadjuvant BionHER study () - Jul 27, 2023 - Abstract #ESMO2023ESMO_1778;
Conclusions In early-stage ERBB2+ BC, a single dose of HP induces significant biological changes that may better predict pCR. At day 8, pts with high expression of HER2DX immune signature and immune-related genes have a higher probability of achieving a pCR following THP.
- trastuzumab imbotolimod (BDC-1001) / Bolt Biotherap
Recommended phase II dose (RP2D) selection and pharmacodynamic (PD) data of the first-in-human immune-stimulating antibody conjugate (ISAC) BDC-1001 in patients (pts) with advanced HER2-expressing solid tumors (Valencia Auditorium - Hall 10) - Jul 27, 2023 - Abstract #ESMO2023ESMO_1368;
P1/2
Conclusions Our novel ISAC BDC-1001 (mono/combo) led to tolerable, encouraging efficacy, translational biomarker data consistent with novel MOA in pts with pretreated HER2+ tumors, particularly at the 20mg/kg q2w RP2D. International phase 2 expansions in HER2+ colorectal, gastroesophageal, and endometrial cancers and a new phase 2 in breast cancer (BDC-1001
- | Herceptin (trastuzumab) / Roche, Neulasta (pegfilgrastim) / Amgen, Kyowa Kirin, Roche, Perjeta (pertuzumab) / Roche
Observational data, Retrospective data, Journal, Real-world evidence, Real-world: Real-world data analysis of perioperative chemotherapy patterns, G-CSF use, and FN status in patients with early breast cancer. (Pubmed Central) - Jul 24, 2023
International phase 2 expansions in HER2+ colorectal, gastroesophageal, and endometrial cancers and a new phase 2 in breast cancer (BDC-1001 Despite the increasing use of escalated regimens in the last 5-6
- | Kadcyla (ado-trastuzumab emtansine) / Roche, Perjeta (pertuzumab) / Roche
Journal, Real-world evidence, Real-world, Metastases: Real-world survival of Danish patients with HER2-positive metastatic breast cancer. (Pubmed Central) - Jul 24, 2023
Patients receiving treatment according to guidelines had a significantly higher median OS compared to patients who did not. We also found that patients with ER-negative disease or high tumor burden had a significantly higher risk of developing brain metastases.